论文部分内容阅读
目的探讨表皮生长因子受体(EGFR)、K-ras基因突变和EML4-KLA融合基因与非小细胞肺癌(NSCLC)患者的临床病理特征的关系。方法收集2012年1月至2014年6月淄博市中心医院住院肺癌患者268例的胸腔积液标本,患者年龄53.6(31~76)岁,其中男165例、女103例。采用免疫组织化学对患者胸腔积液进行分析,确诊为NSCLC 76例,其中腺癌39例,鳞癌37例。检测76例NSCLC的细胞蜡块及肺肿瘤穿刺标本中EGFR、K-ras基因突变及EML4-ALK融合基因。结果 EGFR突变率为34.21%(26/76),K-ras基因的突变率为6.58%(5/76),EML4-ALK融合基因阳性率为7.89%(6/76)。EGFR基因突变、K-ras基因突变或EML4-ALK融合基因多见于不吸烟的、年轻的、女性、腺癌(P<0.05)。未发现EGFR基因突变、K-ras基因突变或EML4-ALK融合基因存在于同一病例,可能与病例数少有关,有待更多研究进一步探讨。结论采用NSCLC胸腔积液细胞学标本进行EGFR、K-ras和EML4-ALK基因检测,方法可行,尤其适用于无法获取组织学标本的NSCLC患者。
Objective To investigate the relationship between epidermal growth factor receptor (EGFR), K-ras gene mutation and EML4-KLA fusion gene and clinicopathological features in patients with non-small cell lung cancer (NSCLC). Methods A total of 268 patients with lung cancer admitted from Zibo Central Hospital from January 2012 to June 2014 were collected. The patients were 53.6 (31-76) years old, of whom 165 were male and 103 were female. Immunohistochemistry in patients with pleural effusion were analyzed, diagnosed as NSCLC 76 cases, including 39 cases of adenocarcinoma, squamous cell carcinoma in 37 cases. 76 cases of NSCLC cell wax block and lung tumor puncture specimens of EGFR, K-ras gene mutation and EML4-ALK fusion gene. Results The mutation rate of EGFR was 34.21% (26/76). The mutation rate of K-ras gene was 6.58% (5/76). The positive rate of EML4-ALK fusion gene was 7.89% (6/76). EGFR gene mutation, K-ras gene mutation or EML4-ALK fusion gene more common in non-smoking, young, female, adenocarcinoma (P <0.05). No EGFR gene mutation, K-ras gene mutation or EML4-ALK fusion gene found in the same case may be related to the small number of cases, to be further studied. Conclusion NSCLC pleural effusion cytology specimens for EGFR, K-ras and EML4-ALK gene detection, the method is feasible, especially for patients with NSCLC can not obtain histological specimens.